Mariana Elizondo-Zertuche1, Efrén Robledo-Leal2, J Gerardo González3, Luis A Ceceñas3, Gloria M González4. 1. Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Departamento de Microbiología, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico. 2. Universidad Autónoma de Nuevo León, UANL, Facultad de Ciencias Biológicas, Av. Universidad S/N Ciudad Universitaria, San Nicolás de los Garza, Nuevo León, C.P. 66451, Mexico. 3. Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Hospital Universitario Dr. José Eleuterio González, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico. 4. Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Departamento de Microbiología, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico. Electronic address: gmglez@yahoo.com.mx.
Abstract
BACKGROUND: The incidence of vulvovaginal candidiasis, a common infection among healthy women primarily caused by the yeast Candida albicans, has increased significantly in recent years. AIMS: The purpose of this study was to compare the efficacy of ravuconazole (RVC) and fluconazole (FLC) in the treatment of experimental C. albicans vaginitis. METHODS: Forty isolates of C. albicans were screened for their in vitro susceptibility to RVC and FLC. A strain of C. albicans that was resistant to FLC (minimum inhibitory concentration [MIC] of >64 μg/ml) was selected for the in vivo study. Treatment regimens for the murine vaginal infection model were (1) 1, 5, 10, and 20 mg/kg RVC once daily, (2) 20 mg/kg RVC twice daily, (3) 20 mg/kg FLC once daily, and (4) 20 mg/kg FLC twice daily. RESULTS: The geometric means of the MIC values at 48 h for all isolates tested were 0.05 and 0.5 μg/ml for RVC and FLC, respectively. Regimens of either RVC or FLC at 20 mg/kg twice daily were more effective to reduce the load of FLC-resistant C. albicans than single dose administration. CONCLUSIONS: Complete eradication of C. albicans from the vagina was not observed with RVC or FLC treatment in the animal model, although RVC treatment showed a lower fungal concentration 14 days after drug administration.
BACKGROUND: The incidence of vulvovaginal candidiasis, a common infection among healthy women primarily caused by the yeastCandida albicans, has increased significantly in recent years. AIMS: The purpose of this study was to compare the efficacy of ravuconazole (RVC) and fluconazole (FLC) in the treatment of experimental C. albicansvaginitis. METHODS: Forty isolates of C. albicans were screened for their in vitro susceptibility to RVC and FLC. A strain of C. albicans that was resistant to FLC (minimum inhibitory concentration [MIC] of >64 μg/ml) was selected for the in vivo study. Treatment regimens for the murinevaginal infection model were (1) 1, 5, 10, and 20 mg/kg RVC once daily, (2) 20 mg/kg RVC twice daily, (3) 20 mg/kg FLC once daily, and (4) 20 mg/kg FLC twice daily. RESULTS: The geometric means of the MIC values at 48 h for all isolates tested were 0.05 and 0.5 μg/ml for RVC and FLC, respectively. Regimens of either RVC or FLC at 20 mg/kg twice daily were more effective to reduce the load of FLC-resistant C. albicans than single dose administration. CONCLUSIONS: Complete eradication of C. albicans from the vagina was not observed with RVC or FLC treatment in the animal model, although RVC treatment showed a lower fungal concentration 14 days after drug administration.